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Immunomodulation with IL-4Ra Antisense Oligonucleotide
Prevents Respiratory Syncytial Virus-Mediated
Pulmonary Disease
Michael J. Ripple,1 Dahui You,1,2 Srinivasa Honnegowda, Joseph D. Giaimo,
Andrew B. Sewell, David M. Becnel, and Stephania A. Cormier

R

espiratory syncytial virus (RSV) is an important cause of
acute respiratory tract infections in infants (and the elderly), causing significant morbidity and mortality. The
World Health Organization estimates the global burden of RSV
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disease at 64 million cases and 160,000 deaths annually. In the
United States, RSV is responsible for 85,000–144,000 infant
hospitalizations annually (1). Health care costs are estimated at
$365–585 million per year (2), and the economic impact, in relation to days lost from work, is greater than that of influenza (3).
Primary RSV infection causes severe bronchiolitis requiring hospitalization in 30–40% of infants, particularly in infants 2–5 mo of
age (4). Interestingly, infants who are younger than 3 mo of age
and who develop RSV bronchiolitis show a persistent increase in
IL-4 production following infection (5) and are at an increased
risk for developing recurrent wheeze/asthma (4, 6–15). Despite an
urgent need, no safe and effective vaccine for RSV exists.
In preclinical mouse models of infantile RSV infection, age at
initial infection determines whether RSV predisposes to long-term
lung dysfunction and dictates the type of immune response (Th1
versus Th2) observed following secondary infection with RSV (16–
19). When primary infection with RSV occurs in the first week of
life, mice develop airway hyperresponsiveness (AHR) that lasts
into adulthood (19). Furthermore, a subsequent RSV infection
elicits enhanced immunopathology, with even greater increases in
AHR (17). In contrast, when primary infection with RSV occurs in
the third week of life (weanling), AHR is not induced in response
to secondary infection, although significant airway inflammation
exists (17).
As the age at primary infection increases, the Th2 response
decreases, and the Th1 response increases. This switch from a Th2
bias to more of a Th1 bias in response to RSV infection occurs at ∼1
wk of age in mice (16, 20), and epidemiological data suggest that
it occurs at ∼4 mo of age in humans (4). Prior to this time point,
there is a window of immunological immaturity that results in an
aberrant response to the virus and primes the host to respond with
an adverse Th2 response upon reinfection later in life (16). Indeed,
the failure of the RSV vaccine of the 1960s is believed to be due,

Downloaded from http://www.jimmunol.org/ by guest on October 1, 2021

Respiratory syncytial virus (RSV) causes significant morbidity and mortality in infants worldwide. Severe RSV infections in
infants cause bronchiolitis, wheeze, and/or cough and significantly increase the risk for developing asthma. RSV pathogenesis is
thought to be due to a Th2-type immune response initiated in response to RSV infection, specifically in the infant. Using a neonatal
mouse system as an appropriate model for human infants, we sought to determine whether local inhibition of IL-4Ra expression
during primary RSV infection in the neonate would prevent Th2-skewed responses to secondary RSV infection and improve longterm pulmonary function. To reduce IL-4Ra expression, antisense oligonucleotides (ASOs) specific for IL-4Ra were administered
intranasally to neonatal mice at the time of primary infection. Mice were initially infected with RSV at 1 wk of age and were
reinfected at 6 wk of age. Administration of IL-4Ra ASOs during primary RSV infection in neonatal mice abolished the
pulmonary dysfunction normally observed following reinfection in the adult. This ablation of pulmonary dysfunction correlated
with a persistent rebalancing of the Th cell compartment with decreased Th2 responses (i.e., reduced goblet cell hyperplasia,
Th2 cells, and cytokine secretion) and increased Th1 responses (i.e., elevated Th1 cell numbers and type I Abs and cytokines). Our
data support our hypothesis that a reduction in the Th2 immune response during primary infection in neonates prevents Th2mediated pulmonary pathology initially and upon reinfection and further suggest that vaccine strategies incorporating IL-4Ra
ASOs may be of significant benefit to infants. The Journal of Immunology, 2010, 185: 4804–4811.
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Materials and Methods
Mice
BALB/c mice were purchased as breeders from Harlan Laboratories
(Indianapolis, IN). All mice were housed in the vivarium at Louisiana State
University Health Sciences Center and were maintained in ventilated
microisolator cages housed in a specific pathogen-free animal facility.
Sentinel mice within this animal colony were negative for Abs to specific
viral and other known mouse pathogens. Breeders were time mated, and
2-day-old pups were used for experiments. All animal protocols were
prepared in accordance with the Guide for the Care and Use of Laboratory
Animals (29) and approved by the Institutional Animal Care and Use
Committee at Louisiana State University Health Sciences Center.

Oligonucleotides: preparation and dosage
IL-4Ra ASOs and mismatch oligonucleotides (MMs) were kindly provided by Isis Pharmaceuticals (Carlsbad, CA). The oligonucleotides were
synthesized and purified as previously described (30). Both oligonucleotides were designed to avoid any murine immune-stimulatory motifs and
were 20 bases in length, with 29-O-methoxyethylribose modification on
bases 1–5 and 16–20 (underlined). Their estimated half-life following
single-dose inhalation studies is 4 d in the mouse lung (30). The sequences
of the ASO and MM are shown below; the mismatched bases are shown in
lower case: ASO: 59-CCGCTGTTCTCAGGTGACAT-39 MM: 59-CCaCTcaTCaCtGcTGACtT-39.
The oligonucleotides were suspended in sterile saline and administered
intranasally (i.n.) to mouse pups at a dose of 100 or 500 mg/kg body weight.
Data for both doses were similar for all experiments. Therefore, we chose
to present all inflammatory data at the highest dose (500 mg/kg body
weight), to demonstrate that administration of the oligonucleotides does
not elicit inflammatory responses greater than that induced by RSV; the

pulmonary function data at the lowest dose (100 mg/kg body weight), to
demonstrate lower dose efficacy; and the cytokine data at both doses (100
and 500 mg/kg body weight), to demonstrate that at higher doses the MM
oligonucleotide has effects that are not due to downregulation of IL-4Ra.
Control pups received sterile saline.

Experimental design
The experimental design is outlined in Fig. 1. IL-4Ra ASO, MM, or saline
was administered i.n. to mice on protocol days 25, 23, 21, and 1. On
protocol day 0 (7 d of age), mice were infected with RSV or were sham
infected. Mice receiving ASO, MM, or saline and infected with RSV are
referred to as AR, MR, and SR, respectively. Those mice receiving saline
and sham-infected are referred to as SHAM. For all secondary infections,
mice were reinfected with RSV (ARR, MRR, SRR) or vehicle (SHAM) on
protocol day 35. Various end points were measured, including IL-4Ra
levels, T cell populations in the lung, pulmonary function, bronchoalveolar
lavage cellularity and cytokine profile, pulmonary viral copy number, lung
histology, and RSV-specific Ab levels in serum, at the indicated time
points.

RSV infection and pulmonary viral load determination
Human RSV strain A-2 was purchased as a sucrose-gradient purified virus
from Advanced Biotechnologies (Columbia, MD). The virus preparation
was determined to be free of bacteria, yeast, and fungi. Seven-day-old
mice (protocol day 0; Fig. 1) were anesthetized with 5% isoflurane and
infected i.n. with 2 3 105 median tissue culture infective dose (TCID50)
per gram body weight of RSV in 10 ml serum-free media (Invitrogen) or
media alone (18, 19). Adult mice (protocol day 39) were similarly infected
with RSV (2 3 105 TCID50/gram body weight) in 50 ml the same media.
To determine lung viral load, we used the TCID50 method of SpearmanKärber, as previously published (19), using whole-lung homogenates
isolated from mice at 6 d postinfection (dpi). Vero cells were seeded on
a 96-well plate and then inoculated with 10-fold serial dilutions of wholelung homogenate. Cells were incubated at 37˚C and 5% CO2 for 4 d; wells
showing syncytia were counted, and TCID50 values were calculated.
Viral load was also quantified using real-time PCR. Lungs were isolated at
6 dpi, quick-frozen in liquid nitrogen, and stored at 280˚C until processing.
RNA was extracted from the lungs with TRIzol reagent (Invitrogen,
Carlsbad, CA), purified with an RNeasy Mini Kit (Qiagen, Valencia, CA),
and treated with DNase (Ambion, Austin, TX). The genomic RNA was then
reverse transcribed into cDNA with an RSV-nucleoprotein (NP)–specific
primer (59-GCGATGTCTAGGTTAGGAAGAA-39) or oligonucleotide (dT)
for GAPDH using the Superscript III-RT kit (Invitrogen) and the following
conditions: 65˚C for 5 min, 4˚C for 1 min, 42˚C for 50 min, and 85˚C for
5 min. The samples were incubated at 4˚C for 1 min, RNase H was added,
and the samples were incubated at 37˚C for 20 min. Real-time PCR was
performed using LUX (Invitrogen) primers specific for RSV-NP: 59-TTGGGTAGTAAGCCTTTGTAa[FAM]G-39 (forward primer) and 59-CTGGTCTTACAGCCGTGATTAGGA-39 (reverse primer), which amplified the
region between nucleotides 544–623 to give an amplicon of 79 bp. After
a 2-min denaturation at 95˚C, PCR cycling conditions were 40 cycles of
95˚C for 10 s, 60˚C for 30 s, and 72˚C for 30 s. This was followed by
a melt-curve analysis: 1 min denaturation at 95˚C, 1 min anneal at 55˚C,
and a 55–90˚C melt-curve (+0.5˚C/cycle; 30 s) in a Bio-Rad iQ5 Machine
(Bio-Rad, Hercules, CA). Selected PCR products were cloned into a TA
cloning vector (pGEM-T; Promega, Madison, WI), and the sequence was
determined to confirm the identity of the virus detected by the PCR reaction. GAPDH internal control (Invitrogen Mouse/Rat GAPDH-Certified
JOE-labeled LUX Primer Set) was used to confirm equal quantities of input
cDNA. RSV-NP copy number was determined from standard curves of
a plasmid vector containing a fragment of the RSV-NP gene.

Isotype determination and quantification of RSV-specific Ab
Serum was isolated from the left ventricle of euthanized mice following
primary infection (7 and 12 dpi) using serum separator tubes (BD Biosciences, Bedford, MA) and was stored at -80˚C until use. Microtiter plates
(Nunc-Immuno Maxisorp, Nalge Nunc International, Rochester, NY) were
coated with 50 ml RSV (5 3 104 PFU/ml) overnight at 4˚C in PBS. The
plates were blocked with 13 Blocker BSA (Pierce, Rockford, IL) for
5 min, and 25 ml serum was added to each well and allowed to incubate for
2 h at room temperature. Bound RSV-specific Ab was then isotyped and
quantified using peroxidase-conjugated goat Abs specific for mouse IgA,
IgG1, IgG2a, and IgE (Southern Biotech, Birmingham, AL) and 3,39,5,59tetramethylbenzidine (Pierce, Rockford, IL) as substrate. Color development was stopped with 2 M H2SO4, and the absorbance was read
at 450 nm. RSV-specific Ab levels were determined by subtracting the
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in part, to the exacerbated Th2 response to community-acquired
RSV following inoculation with formalin-inactivated virus (21).
Understanding this age-related difference in pathophysiological
response to RSV infection is critical to appreciate the problems
associated with the development of an effective pediatric vaccine
for RSV.
IL-4 and IL-13 are classical signaling mediators of the Th2
response. Both of these cytokines bind their respective receptors
containing the IL-4Ra subunit. IL-4 has two receptors: type I and
II. The type I receptor is composed of IL-4Ra and the common
g-chain; it binds IL-4 exclusively and initiates Th2 cell differentiation. The type II IL-4R is composed of the IL-4Ra and IL13Ra1 subunits. It binds IL-4 or IL-13 and is thought to cause the
adverse effects observed following neonatal RSV infection, including AHR, lung remodeling, and mucus hyperproduction (22).
Signaling through both of these receptors occurs via a JAK/STAT
pathway (23) and is important in the neonatal response to RSV.
Inhibition or depletion of IL-4 and/or IL-13 helps to reduce the
adverse effects seen in neonatal infections in mice (17, 24), most
notably decreased AHR and mucus hyperproduction. The recent
association of IL-4/IL-13 haplotypes and IL-4Ra gain-of-function
polymorphisms with RSV hospitalizations and disease severity
(25–28) suggests that IL-4Ra may play a key role in RSVmediated pulmonary pathologies in human infants.
Despite nearly half a century of research, no vaccine has been
clinically approved for RSV, and few viable treatments exist. In this
study, we sought to determine whether reduction of IL-4Ra in the
pulmonary compartment is sufficient to prevent the adverse pulmonary events observed following neonatal RSV infection. To accomplish this, we used an antisense oligonucleotide (ASO) specific
for IL-4Ra to reduce receptor expression. Our results indicate that
suppression of pulmonary IL-4Ra protects from subsequent RSVmediated pulmonary inflammation and lung dysfunction. Our data
further suggest that a pediatric-vaccine strategy employing inhaled
IL-4Ra ASO may be effective to prevent complications of RSVinduced wheeze.

4805

4806
absorbance value of the blank wells (media only) from the absorbance of
each serum sample.

Determination of IL-4Ra surface expression and assessment of
pulmonary T and dendritic cell populations

Assessment of pulmonary function
Six days after secondary infection, lung resistance and compliance to increasing doses of methacholine (MeCh; 0, 12.5, 25, and 50 mg/ml in
isotonic saline; Sigma-Aldrich) were assessed using the forced-oscillation
technique. Animals were anesthetized with ketamine/xylazine (180/10
mg/kg) and mechanically ventilated at a tidal volume of 10 ml/kg and
a frequency of 2.5 Hz using a computer-controlled piston ventilator
(FlexiVent Ver. 5.2R02, SCIREQ, Montreal, Quebec, Canada). Resistance
and compliance data were calculated using the single-compartment model.
For comparison among the groups, all data were normalized to their individual baseline resistance values ([value-baseline]/baseline) and plotted
as normalized resistance. Baseline values were not statistically different
among the groups.

Determination of bronchoalveolar lavage fluid cellularity and
cytokine measurement
Bronchoalveolar lavage fluid (BALF) was isolated in 0.9 ml PBS containing
2% BSA. Total bronchoalveolar lavage cellularity was determined with
a hemocytometer. Cells (20,000) were centrifuged onto slides and were
fixed and stained using the Hema-3 staining kit (Fisher Scientific, Pittsburgh, PA). Two unbiased observers counted 200–300 cells per slide using
standard morphological criteria to classify individual leukocyte populations. Cytokine levels were measured from 50 ml cell-free BALF using
a high-throughput multiplex cytokine assay system (x-Plex Mouse Assay;
Bio-Rad), according to the manufacturer’s instructions. Three to six BALF
samples per group were analyzed in duplicate on the Bio-Plex 200 system
(Bio-Rad). Standards ranging from 0.2 to 6296 pg/ml (depending on the
analyte) were used to quantitate a dynamic range of cytokine concentrations. The concentrations of analytes in the samples were quantified
using a standard curve, and a five-parameter logistic regression was performed to derive an equation that was then used to predict the concentration of the unknown samples. The following cytokines were assayed:
IL-4, IL-5, IL-12(p40), IL-13, and IFN-g. The data presented exclude any
number outside the range of sensitivity for the particular analyte.

Pulmonary histopathology
Lungs were perfused with PBS containing 20 U/ml heparin, inflated gently
to total lung capacity, and fixed in HistoChoice Tissue Fixative
(AMRESCO, Solon, OH) for 24 h at 4˚C. These tissues were then embedded in paraffin, cut in 4-mm frontal sections, and stained with H&E or
periodic acid-Schiff (PAS) to show inflammation and mucus hyperproduction in airway goblet cells, respectively. To evaluate the level of inflammation associated with secondary RSV infection, two independent
observers quantified the total number of airways in each lung section and
then scored each of these airways for inflammation (0, no inflammation; 1,
inflammation at least three cells thick). These data are reported as the
percentage of inflamed airways/total number of airways per lung section.

Statistical analyses
Power analysis was used to determine the appropriate number of subjects for
each experiment. All data were plotted as means 6 SEM and analyzed
using GraphPad Prism software (version 5.02; GraphPad, San Diego, CA).
Two-way ANOVA and Bonferroni post hoc tests were used to test for
differences in the pulmonary function tests between the groups. One-way
ANOVA and Bonferroni post hoc tests were used to test for differences in
BALF cellularity, BALF cytokine levels, Ab levels, lung inflammation, and
T cell populations. The Student t test was used for surface expression of
IL-4Ra. Differences were considered statistically significant at p , 0.05.

Results
Surface expression of IL-4Ra is reduced on pulmonary mDCs
and epithelial cells following IL-4Ra ASO inhalation
IL-4Ra ASOs, which were shown to downregulate IL-4Ra protein
in an adult mouse model of allergic asthma (30), were used to
reduce the expression of IL-4Ra on pulmonary immune and structural cells in the neonatal mouse lung. We administered 500 mg/kg
of IL-4Ra ASO or MM i.n. to neonatal mice on days 25, 23, and
21 (Fig. 1). On protocol day 0 (i.e., 7 d of age), lung cells were
recovered after collagenase digestion of the tissue and analyzed for
surface expression of IL-4Ra. Downregulation of IL-4Ra protein
on the surface of specific lung cell populations was determined
using flow cytometry (Fig. 2). The mean fluorescence intensity
(MFI) of IL-4Ra was significantly reduced on mDC populations by
21 6 1.6% and on E-cadherin+ epithelial cells by 12.5 6 3.0%
(mean 6 SEM) compared with saline (vehicle) controls. The decreased MFI data for epithelial cells and mDCs paralleled the reduction in the percentage of IL-4Ra–expressing cells. No difference
in IL-4Ra expression levels by MFI was observed on CD4+ or CD8+
T cells. There was a slight, but significant, reduction in the percentage of CD4+ cells expressing IL-4Ra compared with saline, as
well as a decrease in the percentage of epithelial cells expressing IL4Ra (Fig. 2B). Similar to previous studies, administration of MM
had no effect on IL-4Ra expression levels, as assessed by MFI of
IL-4Ra or by the percentage of IL-4Ra–expressing cells. Because
absorption of inhaled ASO into the systemic circulation is ,1% of
the deposited lung dose (30), IL-4Ra expression in other tissues was
not assessed. These observations indicate that inhaled ASO effectively targets mDCs in the neonatal lung.
Downregulation of IL-4Ra during primary RSV infection
increases Th1 cellular and Ab response
Because signaling through IL-4Ra is required for Th2 differentiation, downregulation of IL-4Ra should significantly impair the
development and differentiation of Th2 cells. To test this theory,
we treated mice with IL-4Ra ASO, infected them with RSV, and
measured T cell populations at 6 dpi (Fig. 1). RSV infection elicited an increase in pulmonary Th2 (CD4+IL4+) cell populations
compared with control mice (SR, 0.347 6 0.033% versus SHAM,
0.033 6 0.003% or, Fig. 3). Treatment with IL-4Ra ASO significantly reduced the percentage of Th2 cells in the lungs of
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A single-cell suspension of lung cells was prepared using a standardized
protocol (31). Lungs were perfused, excised, cut into small pieces, and
incubated at 37˚C for 1 h in RPMI 1640 media (HyClone, Logan, UT)
supplemented by 5% heat-inactivated FBS (HyClone), 100 U/ml penicillin,
100 mg/ml streptomycin (HyClone), 1 mg/ml collagenase I (Invitrogen),
and 150 mg/ml DNase I (Sigma-Aldrich, St. Louis, MO). After incubation,
single cells were obtained by mashing the lung pieces through a 40-mm
cell strainer (BD Biosciences, San Jose, CA). RBCs were lysed using
RBC lysis buffer (eBioscience), and cells were stained with combinations
of the following Abs purchased from BD Biosciences and eBioscience
(San Diego, CA): Pacific Blue-CD3e (17A2), PerCP-CD4 (RM4-5), FITCCD8a (53-6.7), Biotin-CD124 (mIL4R-M1), allophycocyanin-CD11b (M1/70),
PE Cy7-CD11c (N418), and FITC-E-cadherin (36/E-cadherin).
For determining T cell subsets, lung cells (single-cell suspensions
prepared as above and after RBC lysis) were stimulated for 5 h with 5 ng/ml
PMA and 500 ng/ml ionomycin (Sigma-Aldrich) in the presence of
a protein-transport inhibitor (1 ml/106 cells; GolgiPlug, BD Biosciences).
After stimulation, cells were harvested, stained for surface markers
(i.e., CD3, CD4, and CD8), fixed, permeabilized (Fixation and Permeabilization Buffer; eBioscience), and stained with PE–IFN-g (XMG1.2)
to identify Th1/Tc1 cells and PE-Cy7-IL-4 (BVD4-24G2) to identify Th2/
Tc2 cells. Cell staining was determined with a FACSCanto II (BD Biosciences) flow cytometer after gating on specific live cell populations, as
determined by forward and side scatter properties, and on CD3+ cells for
T cell population analyses. A total of 100,000 events were analyzed per
mouse lung.
For determining myeloid dendritic cell (mDC) subsets, lung cells (singlecell suspensions prepared as above and after RBC lysis) were stained for
surface expression of CD11b and CD11c. After selecting the live nonlymphocyte, nonmonocyte cells using forward and side scatter properties,
expression of CD11chi and CD11b+ was used to identify mDCs. A total of
300,000 events were analyzed per mouse lung. Isotype control Abs were
used in all flow-cytometry experiments. Flow data were analyzed and
plotted using FlowJo software (version 7.2.2 for Windows; Tree Star,
Ashland, OR).

ANTISENSE IL-4Ra PREVENTS RSV PATHOGENESIS

The Journal of Immunology

RSV-infected mice (AR, 0.127 6 0.032%) compared with the SR
group. Th1 (CD4+IFN-g+) cell populations were increased in RSVinfected mice compared with controls (0.280 6 0.025% versus
0.040 6 0.006% for SR and SHAM, respectively), and ASO
treatment further increased this Th1 population (AR, 0.767 6
0.048%). These data indicate that treatment with IL-4Ra ASO
significantly shifts the initial immune response to RSV infection
toward a Th1 profile.
Tc2 (CD8+IL-4+) cells, another important source of IL-4, were
increased in the SR group compared with controls (0.217 6
0.058% and 0.043 6 0.003%, respectively) and were reduced in the
MR and AR groups compared with controls (0.110 6 0.012% and
0.087 6 0.018%, respectively), although neither achieved statistical significance. Tc1 (CD8+IFN-g+) cells, which are important in
viral clearance, were significantly increased in the SR group
compared with controls (2.27 6 0.113% and 0.033 6 0.003%,

FIGURE 3. T cell subpopulations after primary infection with RSV. The
AR group was treated with 500 mg/kg IL-4Ra ASO or MM on protocol
days 25, 23, 21, and 1 and infected with RSV on protocol day 0. The SR
group was treated with saline and infected with RSV. Control (SHAM)
mice were treated with saline and sham infected with vehicle. Six dpi, lung
cells were isolated and stained with differentiation markers and analyzed
by flow cytometry. Th1 cells (CD4+IFN-g+), Th2 cells (CD4+IL4+), Tc1
cells (CD8+IFN-g+), and Tc2 cells (CD8+IL4+) in the lung were analyzed.
Data are representative of three independent experiments and are
expressed as means 6 SEM (n = 3/group). pp , 0.05, compared with
SHAM; #p , 0.05, compared with SR.

respectively) and seemed to be unaffected by ASO administration
(2.397 6 0.148%). There were no differences in the percentage
of T cell subsets (i.e., Th2, Th1, Tc2, Tc1) in the SR and MR
groups. Similar trends were also observed when the total numbers
of each of these T cell subsets were calculated (Supplemental
Fig. 1).
Because the isotype of Abs produced in response to a pathogen is
another indicator of the type of immune response initiated (i.e., Th1
versus Th2), we analyzed RSV-specific Ab isotypes by indirect
ELISA in sera of mice infected with RSV as neonates with or
without IL-4Ra ASO treatment. At 7 dpi, neonatal RSV infection
(SR) resulted in detectable levels of IgG1, IgG2a, IgE, and IgA
(Fig. 4A). However, treatment with IL-4Ra ASO during neonatal
RSV infection significantly boosted IgG2a levels compared with
controls (AR: 2.31 6 0.58-fold greater than SR and 2.09 6 0.54fold greater than MR). By 12 dpi (Fig. 4B), IgG2a remained elevated in the sera of IL-4Ra ASO-treated mice, suggesting that
suppression of IL-4Ra expression results in elevated Th1-like IgG2a
responses to neonatal RSV infection. Ab isotypes produced in response to RSV infection were similar between the SR and MR
groups at 7 and 12 dpi.
IL-4Ra ASO treatment has no effect on viral load during RSV
infection
Pulmonary viral load may be associated with increased disease
severity in some human cases (32). To address the possible effects

FIGURE 2. Cell surface expression of IL-4Ra and percentage of IL4Ra1 cells after inhalation of ASO in neonatal mice. The ASO group was
treated with 500 mg/kg IL-4Ra ASO on protocol days 25, 23, and 21.
The MM group was treated with 500 mg/kg MM. Saline mice were treated
with saline. On protocol day 0 (age 7 d), lung cells were isolated, labeled
with differentiation markers, and analyzed by flow cytometry. A, MFI of
IL-4Ra on pulmonary cell subsets. B, Percentage of IL-4Ra+ cells of each
cellular subset. CD4, CD4+ T cells (CD3+, CD4+, IL-4Ra+); CD8, CD8+
T cells (CD3+, CD8+, IL-4Ra+); Epi (E cadherin+, IL-4Ra+); mDC
(CD11bhi, CD11c+, IL-4Ra+). Data are representative of three independent
experiments and are expressed as means 6 SEM (n = 4/group). pp , 0.05,
compared with saline; jp , 0.05, compared with MM. Epi, epithelial cells.

FIGURE 4. Serum Ab isotypes after primary RSV infection at 7 dpi (A)
and 12 dpi (B). RSV-specific Abs in serum were determined by indirect
ELISA. Absorbance values (OD) are plotted. Data are representative of
two independent experiments. Dose of ASO or MM was 500 mg/kg (n =
4–6/group). #p , 0.05, compared with SR.
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FIGURE 1. Study timeline and group summary. Mice were treated with
IL-4Ra ASO (AR/ARR), MM (MR/MRR), or saline (SR/SRR and SHAM)
on protocol days 25, 23, 21, and 1 and infected with RSV (AR/ARR,
MR/MRR, and SR/SRR) or vehicle (SHAM) on protocol day 0. For secondary studies, mice were reinfected with RSV (ARR, MRR, and SRR) or
vehicle (SHAM) on protocol day 35. Various end points were measured:
IL-4Ra levels on pulmonary cells (IL-4Ra levels), RSV-specific Ab levels
in serum (Ab isotypes), viral load (RSV copy number in the lung), T cell
populations in the lung (T pop), pulmonary function testing (PFT), cell
differential counts in BALF (BALF), lung histology (Histo); and BALF
cytokines (CK).
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ANTISENSE IL-4Ra PREVENTS RSV PATHOGENESIS
IL-4Ra ASO treatment provides long-term pulmonary
protection even after rechallenge with RSV
Data from the failed RSV vaccine trials of the 1960s indicated that
vaccinated children suffered from enhanced bronchiolitis and
respiratory disease with community-acquired RSV compared
with unvaccinated children. To determine whether treatment
with IL-4Ra ASO was capable of preventing enhanced respiratory
disease following reinfection with RSV, we treated neonatal mice
with IL-4Ra ASO during primary RSV infection. Five weeks
later, these same mice were reinfected with RSV. Six days after
secondary infection (protocol day 42), airway function and inflammation were assessed in these animals.

of ASO treatment on RSV replication in the lung, we assessed
viral load using traditional TCID50 methodology and real-time
PCR to determine pulmonary RSV-NP copy numbers. Viral
loads were measured at 6 dpi. Viral load in the lungs of ASOtreated, RSV-infected mice (AR group) was similar to control
mice infected with RSV but not receiving ASO (SR group) or
mice receiving MM (MR group). The TCID50 for RSV was 781 6
219 in the lungs of the AR group and 765 6 72 in the lungs of the
SR group. The cycle threshold values for RSV-NP were 30.2 6
0.662, 30.3 6 0.213, and 30.8 6 0.426 for the SR, AR, and MR
groups, respectively. Cycle threshold values for the reference
gene, GAPDH, were also similar (20.0 6 0.710, 19.5 6 0.663,
and 18.6 6 0.685 for the SR, AR, and MR groups, respectively),
indicating that equivalent amounts of experimental sample were
analyzed. No viral particles were detected in the lungs of any mice
after 8 dpi during primary or secondary infection, suggesting that
IL-4Ra ASO treatment does not hinder viral clearance during
primary or secondary infection.

FIGURE 6. Histology after secondary RSV infection. Lung tissue was obtained at 6 d after secondary
infection. A, H&E staining shows inflammatory cells
in the lung (arrows). Original magnification 3100;
scale bar, 50 mm. B, Staining with PAS shows mucus
production in airway epithelial cells. Original magnification 3400; scale bar, 200 mm. C, Morphometric
analysis of lung inflammation and mucus. Data are
expressed as mean percentage of inflamed airways to
total airways or as mean mucus index as quantified from
frontal sections of the lungs from each mouse. The
mucus index was determined as follows: ([area of PAS
staining/total area of the airway epithelium] 3 number
of airways counted per lung). Dose of ASO or MM was
100 mg/kg to demonstrate efficacy at a lower dose.
Micrographs are representative of three independent
experiments and are expressed as means 6 SEM
(n = 4 mice/group). pp , 0.05, compared with SHAM;
#
p , 0.05, compared with SRR.

Pulmonary histopathology. Histological evaluation was performed
on lung sections obtained 6 d after secondary infection. Significant
inflammation was visible in the peribronchiolar and perivascular
areas in the lungs of mice infected with RSV (SRR group) or treated
with MM and subsequently infected with RSV (MRR group).
Pulmonary inflammation was significantly diminished by ASO
administration (ARR group; Fig. 6A, 6C, Supplemental Fig. 2).
Mice reinfected with RSV exhibited markedly enhanced mucus
production; this effect was mostly abolished with IL-4Ra ASO
treatment at the time of primary infection (Fig. 6B, 6C). These
data correlate with the increased airway resistance observed after
secondary infection in the SRR group and the reduction of airway
resistance to baseline levels in the ARR group (Fig. 5).
BALF cellularity. The total number of leukocytes recovered in the
BALF of all RSV-infected mice was significantly elevated after
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FIGURE 5. Pulmonary function after secondary RSV infection. Mice
were treated with ASO, MM, or saline, infected with RSV or sham infected
as neonates, and reinfected with RSV at 6 wk of age (ARR, MRR, SRR,
and SHAM, respectively). Six days later, pulmonary function was measured in all four groups. Lung resistance (A) and compliance (B) were
measured in response to increasing doses of MeCh. Resistance values were
normalized to individual baseline resistance at 0 mg/ml MeCh. Dose of
ASO or MM was 100 mg/kg to demonstrate efficacy even at lower dose.
Data are representative of three independent experiments and are
expressed as means 6 SEM (n = 6/group). pp , 0.05, compared with
SHAM; #p , 0.05, compared with SRR.

Pulmonary function. The SRR group showed significant increases
in airway resistance compared with SHAM mice at the 500 and 100
mg/kg doses (data not shown and Fig. 5A, respectively). IL-4Ra
ASO treatment during the initial infection provided protection
from AHR in response to secondary RSV infection. In fact, lung
resistance at 50 mg/ml of MeCh in the SRR group was ∼2.5-fold
higher than in the SHAM or ARR group at the 100 mg/kg dose
of ASO. Lung compliance followed the same trend (Fig. 5B).
Compliance in the ARR group was similar to that in the SHAM
mice, whereas the SRR group showed substantially lower compliance at 50 mg/ml of MeCh (1.5-fold) compared with the SHAM
or ARR groups. Treatment with MM during initial RSV infection
(MRR group) failed to alter pulmonary resistance or compliance
following secondary RSV infection compared with infection alone
(SRR group).
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reinfection at 5 wk (Fig. 7). This increase seemed to be due
primarily to increases in macrophage/monocyte and lymphocyte
populations. IL-4Ra ASO treatment during primary infection significantly reduced the total number of leukocytes present in the
BALF following reinfection with RSV (ARR group), and these
decreases were mainly due to a reduction in macrophage and
lymphocyte numbers. Although not statistically different, BALF
eosinophil numbers were slightly reduced from mice receiving IL4Ra ASO treatment compared with those not receiving treatment
(2.1 3 103 versus 5.0 3 103 for ARR and SRR, respectively; p =
0.14).
Th1 cell subsets and cytokine responses are maintained in the
adult mouse upon rechallenge with RSV

FIGURE 7. BALF cellularity after secondary RSV infection. Mice were
treated with ASO, MM, or saline; infected with RSV or sham infected as
neonates; and reinfected at 6 wk of age (ARR, MRR, SRR, and SHAM,
respectively). Six days later, BALF was collected, and WBC differentials
were counted. Dose of ASO or MM was 500 mg/kg. Data are representative of three independent experiments and are expressed as means 6
SEM (n = 6–10/group). Two independent observers counted 200–300 cells
per mouse. pp , 0.05, compared with SHAM; #p , 0.05, compared with
SRR. Eos, eosinophils; Lym, lymphocytes; Mac, macrophages; Neu,
neutrophils.

differences were observed between the ARR group and nontreated
mice (SRR group) for other cytokines, including the prominent
Th1 cytokines IL-12 and IFN-g.

Discussion
The age of primary infection with RSV is important in dictating
the initial and subsequent immunological responses to infection.
Neonatal RSV infection results in the development of persistent
pulmonary dysfunction in humans (4) and mice (16–19), as the
result of an immature immune system in the neonates. Therefore,
manipulation of the immune system during this window of immunological immaturity may provide significant long-term respiratory benefit to neonates infected with RSV and yield an
opportunity for effective vaccination. Data from the present study
support our hypothesis that the administration of IL-4Ra ASO
during neonatal RSV infection rebalances the Th cell compartment, decreasing Th2 responses (i.e., reduced goblet cell hyperplasia and Th2 cytokine secretion) and increasing Th1 responses
(i.e., elevated Th1 cell numbers and type I Abs and cytokines).
Administration of IL-4Ra ASO reduced multiple pathophysiological parameters associated with neonatal RSV infection, including pulmonary inflammation and mucus hyperproduction.

FIGURE 9. BALF cytokine levels after secondary RSV infection. Following secondary RSV infection, BALF was isolated at 6 dpi, and the cellfree supernatant was analyzed for the following cytokines: IL-4, IL-5,
IL-12(p40), IL-13, and IFN-g. Dose of ASO or MM was 500 mg/kg. Data
are representative of three independent experiments and are expressed as
means 6 SEM (n = 4/group). pp , 0.05, compared with SHAM; #p ,
0.05, compared with SRR.
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Unlike in adult mouse models in which primary infection with RSV
induces predominant Th1 responses, primary infection with RSV in
neonates induces Th2 responses upon reinfection and is associated
with enhanced disease (i.e., Th2 cell expansion, IL-4 production,
and eosinophilia) (16, 33, 34). To address the possible mechanisms
by which IL-4Ra ASO treatment alleviated pulmonary disease
upon RSV reinfection, T cell responses (i.e., Th1/Th2 and Tc1/
Tc2 responses) were investigated 6 d after reinfection (Fig. 8).
Th1, Th2, Tc1, and Tc2 cells migrated to lungs, as evidenced by
significantly greater numbers of all four cell types in the lungs of
RSV-reinfected mice (SRR and ARR groups) than in the SHAM
mice. The lungs from mice infected with RSV as neonates and
reinfected as adults (SRR group) contained significantly greater
numbers of Th2 cells (1.88 6 0.148%) compared with control
mice (SHAM, 0.220 6 0.061%). Administration of IL-4Ra ASO
at the time of primary infection significantly reduced the Th2
population in the lungs upon secondary infection (ARR, 1.00 6
0.188%) compared with the SRR group. Tc1 and Tc2 populations
were significantly increased in response to secondary RSV infection
compared with uninfected controls. Administration of IL-4Ra ASO
also increased Tc1 levels (ARR, 26.4 6 3.10%) compared with the
SRR (18.4 6 1.76%) and SHAM groups. Similar data were observed in the total numbers of T cell subsets (Supplemental Fig. 1)
BALF cytokine levels were also measured 6 d following secondary infection (Fig. 9). RSV reinfection resulted in secretion of
a variety of cytokines, including IL-4, -5, -12(p40), and -13 and
IFN-g. IL-4Ra ASO treatment (ARR group) during primary infection in neonatal mice led to a reduction in Th2 cytokines, including IL-5 and IL-13, following secondary infection. The
decreased Th2 cytokine production in the BALF was consistent
with the reduced AHR and mucus observed in the ARR group. No

FIGURE 8. T cell populations after secondary RSV infection. Mice
were treated with ASO, MM, or saline on protocol days 25, 23, 21, and
1; infected with RSV on protocol day 0; and reinfected with RSV on
protocol day 35. Six days after secondary infection (protocol day 41), lung
cells were isolated, stimulated in vitro with ionomycin and PMA, stained
with differentiation markers, and analyzed by flow cytometry. Th1 cells
(CD4+IFN-g+), Th2 cells (CD4+IL4+), Tc1 cells (CD8+IFN-g+), and Tc2
cells (CD8+IL4+) in the lung were measured. Dose of ASO or MM was
500 mg/kg. Data are representative of three independent experiments and
are expressed as means 6 SEM (n = 4/group). pp , 0.05, compared with
SHAM; #p , 0.05, compared with SRR.
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on–off effect; however, it was sufficient to properly alter the Th1/
Th2 balance and to ensure that the immune responses to RSV
reinfection were beneficial, as evidenced by the fact that pulmonary function, inflammation, and mucus production in ASOtreated mice were more similar to noninfected controls. The importance of the fine balance between Th1 and Th2 responses to
a viral infection is well recognized in many studies, and it was
eloquently demonstrated in a study in which rRSV expressing
IFN-g was used to infect mice with the hope of preventing pulmonary disease following RSV reinfection (38). Unfortunately,
overexpression of IFN-g, the canonical Th1/Tc1 cytokine, during
primary infection in adults led to detrimental effects, including
enhanced weight loss and more severe pulmonary inflammation
upon reinfection. A follow-up study using rRSV expressing IL-4
or IFN-g in neonates showed that neonatal mice infected with
RSV expressing IFN-g have increased maturation of immune cells
responsible for the innate response (39). This reduces neutrophil
and NK cell recruitment upon rechallenge with RSV, which is
mediated by macrophages. Priming the neonate with RSV in an
environment rich in IFN-g may help to promote the maturation of
macrophages, thereby preventing neutrophil- and NK cellmediated pathology upon rechallenge as an adult. In contrast,
administration of IL-4Ra ASO moderately increased Th1
responses while significantly reducing the pulmonary pathology
(i.e., AHR and mucus hyperproduction) characteristic of neonatal
RSV reinfection.
Recent data using an adult model of RSV infection demonstrated
that inhibiting IL-13 expression or function may promote Th17
inflammation (40). Although we observed decreased levels of
IL-13 in the BALF of RSV-infected pups treated with IL-4Ra
ASO, IL-17 levels were not statistically different from salinetreated, SHAM-infected controls (data not shown). This suggests
that, at least in our neonatal model of RSV infection, the use of IL4Ra ASO does not have the unintended consequence of upregulating Th17 cytokine production.
Despite almost half a century of intense research, there is no
vaccine available for RSV. One of the major reasons is that the
usual vaccination strategy uses an attenuated virus to inoculate
infants with the hope of eliciting protective memory responses in
a rather immature or weakened immune system. As an alternative,
we used a wild-type virus to infect neonatal mice along with
immunomodulation at the time of infection. The results, so far, are
promising. We demonstrated that treating neonates with ASO
specific for IL-4Ra during primary RSV infection completely protects against the pulmonary dysfunction usually observed following RSV reinfection. This protection was achieved by inducing
a sufficiently strong immune response with a wild-type virus instead of an attenuated one, as well as by delicately balancing Th1
and Th2 responses with IL-4Ra ASO treatment during infection.
We believe that our IL-4Ra ASO treatment offers a good opportunity for future vaccine-development strategies and suggest its
potential use as a therapeutic for pediatric RSV infection.
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Furthermore, it completely abolished the development of AHR
following adult reinfection with RSV and altered the initial and
subsequent T cell responses to RSV infection, demonstrating its
potential as part of a vaccine strategy.
Administration of IL-4Ra ASO significantly downregulated
IL-4Ra on neonatal pulmonary cells, including mDCs, suggesting
that IL-4Ra mediates T cell rebalancing via modulation of pulmonary mDC development and function. Sriram et al. (35) demonstrated that IL-4 suppresses the maturation of DCs (e.g.,
expression of costimulatory molecules, antiviral genes) by rendering the DC less responsive to type I IFNs. They further demonstrated that the lack of responsiveness of the DCs to type I IFNs
attenuated the autocrine positive feedback response required to
generate high levels of type I IFNs via suppression of STAT1
transcription. Although it was beyond the scope of this study to
explore this mechanism in greater detail, we observed substantially reduced levels of type I IFN responses in neonatal RSV
infection compared with responses in adult RSV infection (data
not shown). Because type I IFN signaling is required for DCs to
help initiate and maintain the Th1 response, these data suggest
that DCs developing in the presence of IL-4/IL-13 are helping to
initiate or maintain a Th2 immune response. More importantly, our data suggest that the use of IL-4Ra ASO helps to rebalance the Th cell compartment in response to neonatal RSV
infection. In addition, administration of IL-4Ra ASO resulted in
reduction of IL-4Ra expression on lung epithelial cells and might
account, in part, for the reduced production of goblet cells and
mucus (36).
Overall, our studies reveal a role for IL-4Ra in the pathogenesis
of neonatal RSV infection, which agrees with previous studies
demonstrating that IL-4 (24) and IL-13 (17, 19, 24) are central
mediators in RSV-mediated airways disease in mouse models.
More importantly, our findings support recent data from human
studies indicating that gain-of-function variants of IL-4Ra (26)
play a major role in increasing the severity of RSV disease that
occurs as a result of neonatal RSV infection. The concentration of
IL-13 in the BALF isolated after primary (data not shown) and
secondary RSV infection was significantly reduced in IL-4Ra
ASO-treated mice compared with untreated controls. This decrease in IL-13 correlated with decreased Th2 cells in the lung,
significantly reduced mucus production in pulmonary epithelial
cells, and normal pulmonary function in ASO-treated mice following secondary RSV infection. These data are consistent with
a series of recently published studies demonstrating the importance of IL-13 in RSV-mediated pathophysiology (17, 24). The
mechanism(s) via which IL-4Ra ASO treatment during primary
RSV infection decrease IL-13 concentrations during reinfection
was not explored in this study, but it may simply be due to the
reduced numbers of Th2 cells present after primary and secondary
RSV infection in the ASO-treated groups.
Our study clearly indicates that reduction of IL-4Ra in the lung
at the time of initial infection inhibits the development of Th2 cell
subsets following RSV infection. In light of recent data from
Zaghouani’s laboratory demonstrating the IL-4/IL-13–dependent
specific deletion of Th1 cells in neonates (20, 37), our data further
suggest that downregulating a component of the type II IL-4R
complex allows for the survival of Th1 cells in the presence of
Th2 cytokines, such as IL-4 and IL-13. In support of this theory,
we observed increased numbers of Th1 cells following primary
RSV infection in ASO-treated mice (Fig. 3).
IL-4Ra ASO treatment changed the primary T cell responses to
RSV in infected neonates. Analysis of T cell populations and Ab
isotypes showed that ASO treatment increased the Th1 response
and decreased the Th2 response to RSV. This change was not an

ANTISENSE IL-4Ra PREVENTS RSV PATHOGENESIS

The Journal of Immunology

References

22. Webb, D. C., Y. Cai, K. I. Matthaei, and P. S. Foster. 2007. Comparative roles of
IL-4, IL-13, and IL-4Ralpha in dendritic cell maturation and CD4+ Th2 cell
function. J. Immunol. 178: 219–227.
23. LaPorte, S. L., Z. S. Juo, J. Vaclavikova, L. A. Colf, X. Qi, N. M. Heller,
A. D. Keegan, and K. C. Garcia. 2008. Molecular and structural basis of cytokine
receptor pleiotropy in the interleukin-4/13 system. Cell 132: 259–272.
24. Dakhama, A., Y. M. Lee, H. Ohnishi, X. Jing, A. Balhorn, K. Takeda, and E. W.
Gelfand. 2009. Virus-specific IgE enhances airway responsiveness on reinfection
with respiratory syncytial virus in newborn mice. J. Allergy Clin. Immunol. 123:
138–145.e5.
25. Choi, E. H., H. J. Lee, T. Yoo, and S. J. Chanock. 2002. A common haplotype of
interleukin-4 gene IL4 is associated with severe respiratory syncytial virus disease in Korean children. J. Infect. Dis. 186: 1207–1211.
26. Hoebee, B., E. Rietveld, L. Bont, M. Oosten, H. M. Hodemaekers,
N. J. Nagelkerke, H. J. Neijens, J. L. Kimpen, and T. G. Kimman. 2003. Association of severe respiratory syncytial virus bronchiolitis with interleukin-4
and interleukin-4 receptor alpha polymorphisms. J. Infect. Dis. 187: 2–11.
27. Puthothu, B., M. Krueger, J. Forster, and A. Heinzmann. 2006. Association
between severe respiratory syncytial virus infection and IL13/IL4 haplotypes.
J. Infect. Dis. 193: 438–441.
28. Openshaw, P. J. M. 2005. Antiviral immune responses and lung inflammation
after respiratory syncytial virus infection. Proc. Am. Thorac. Soc. 2: 121–125.
29. Institute of Laboratory Animal Research, Commission on Life Sciences, National Research Council. 1996. Guide for the Care and Use of Laboratory
Animals. National Academies Press, Washington, D.C.
30. Karras, J. G., J. R. Crosby, M. Guha, D. Tung, D. A. Miller, W. A. Gaarde,
R. S. Geary, B. P. Monia, and S. A. Gregory. 2007. Anti-inflammatory activity of
inhaled IL-4 receptor-alpha antisense oligonucleotide in mice. Am. J. Respir.
Cell Mol. Biol. 36: 276–285.
31. You, D., M. Ripple, S. Balakrishna, D. Troxclair, D. Sandquist, L. Ding,
T. A. Ahlert, and S. A. Cormier. 2008. Inchoate CD8+ T cell responses in
neonatal mice permit influenza-induced persistent pulmonary dysfunction.
J. Immunol. 181: 3486–3494.
32. Fodha, I., A. Vabret, L. Ghedira, H. Seboui, S. Chouchane, J. Dewar,
N. Gueddiche, A. Trabelsi, N. Boujaafar, and F. Freymuth. 2007. Respiratory
syncytial virus infections in hospitalized infants: association between viral load,
virus subgroup, and disease severity. J. Med. Virol. 79: 1951–1958.
33. Hussell, T., L. C. Spender, A. Georgiou, A. O’Garra, and P. J. Openshaw. 1996.
Th1 and Th2 cytokine induction in pulmonary T cells during infection with
respiratory syncytial virus. J. Gen. Virol. 77: 2447–2455.
34. Spender, L. C., T. Hussell, and P. J. Openshaw. 1998. Abundant IFN-gamma
production by local T cells in respiratory syncytial virus-induced eosinophilic
lung disease. J. Gen. Virol. 79: 1751–1758.
35. Sriram, U., C. Biswas, E. M. Behrens, J.-A. Dinnall, D. K. Shivers,
M. Monestier, Y. Argon, and S. Gallucci. 2007. IL-4 suppresses dendritic cell
response to type I interferons. J. Immunol. 179: 6446–6455.
36. Kelly-Welch, A. E., M. E. F. Melo, E. Smith, A. Q. Ford, C. Haudenschild,
N. Noben-Trauth, and A. D. Keegan. 2004. Complex role of the IL-4 receptor
alpha in a murine model of airway inflammation: expression of the IL-4 receptor
alpha on nonlymphoid cells of bone marrow origin contributes to severity of
inflammation. J. Immunol. 172: 4545–4555.
37. Li, L., H. H. Lee, J. J. Bell, R. K. Gregg, J. S. Ellis, A. Gessner, and
H. Zaghouani. 2004. IL-4 utilizes an alternative receptor to drive apoptosis of
Th1 cells and skews neonatal immunity toward Th2. Immunity 20: 429–440.
38. Harker, J., A. Bukreyev, P. L. Collins, B. Wang, P. J. M. Openshaw, and
J. S. Tregoning. 2007. Virally delivered cytokines alter the immune response to
future lung infections. J. Virol. 81: 13105–13111.
39. Harker, J. A., D. C. Lee, Y. Yamaguchi, B. Wang, A. Bukreyev, P. L. Collins,
J. S. Tregoning, and P. J. Openshaw. 2010. Delivery of cytokines by recombinant
virus in early life alters the immune response to adult lung infection. J. Virol. 84:
5294–5302.
40. Newcomb, D. C., W. Zhou, M. L. Moore, K. Goleniewska, G. K. Hershey,
J. K. Kolls, and R. S. Peebles, Jr. 2009. A functional IL-13 receptor is expressed
on polarized murine CD4+ Th17 cells and IL-13 signaling attenuates Th17
cytokine production. J. Immunol. 182: 5317–5321.

Downloaded from http://www.jimmunol.org/ by guest on October 1, 2021

1. Hall, C. B., G. A. Weinberg, M. K. Iwane, A. K. Blumkin, K. M. Edwards,
M. A. Staat, P. Auinger, M. R. Griffin, K. A. Poehling, D. Erdman, et al. 2009.
The burden of respiratory syncytial virus infection in young children. N. Engl.
J. Med. 360: 588–598.
2. Stang, P., N. Brandenburg, and B. Carter. 2001. The economic burden of respiratory syncytial virus-associated bronchiolitis hospitalizations. Arch. Pediatr.
Adolesc. Med. 155: 95–96.
3. Fleming, D. M., A. J. Elliot, and K. W. Cross. 2007. Morbidity profiles of
patients consulting during influenza and respiratory syncytial virus active periods. Epidemiol. Infect. 135: 1099–1108.
4. Wu, P., W. D. Dupont, M. R. Griffin, K. N. Carroll, E. F. Mitchel, T. Gebretsadik,
and T. V. Hartert. 2008. Evidence of a causal role of winter virus infection during
infancy in early childhood asthma. Am. J. Respir. Crit. Care Med. 178: 1123–1129.
5. Kristjansson, S., S. P. Bjarnarson, G. Wennergren, A. H. Palsdottir, T. Arnadottir,
A. Haraldsson, and I. Jonsdottir. 2005. Respiratory syncytial virus and other
respiratory viruses during the first 3 months of life promote a local TH2-like
response. J. Allergy Clin. Immunol. 116: 805–811.
6. Sims, D. G., M. A. Downham, P. S. Gardner, J. K. Webb, and D. Weightman.
1978. Study of 8-year-old children with a history of respiratory syncytial virus
bronchiolitis in infancy. BMJ 1: 11–14.
7. Pullan, C. R., and E. N. Hey. 1982. Wheezing, asthma, and pulmonary dysfunction 10 years after infection with respiratory syncytial virus in infancy.
Br. Med. J. (Clin. Res. Ed.) 284: 1665–1669.
8. McConnochie, K. M., and K. J. Roghmann. 1984. Bronchiolitis as a possible
cause of wheezing in childhood: new evidence. Pediatrics 74: 1–10.
9. Mok, J. Y., and H. Simpson. 1984. Outcome for acute bronchitis, bronchiolitis,
and pneumonia in infancy. Arch. Dis. Child. 59: 306–309.
10. Murray, M., M. S. Webb, C. O’Callaghan, A. S. Swarbrick, and A. D. Milner. 1992.
Respiratory status and allergy after bronchiolitis. Arch. Dis. Child. 67: 482–487.
11. Noble, V., M. Murray, M. S. Webb, J. Alexander, A. S. Swarbrick, and
A. D. Milner. 1997. Respiratory status and allergy nine to 10 years after acute
bronchiolitis. Arch. Dis. Child. 76: 315–319.
12. Stein, R. T., D. Sherrill, W. J. Morgan, C. J. Holberg, M. Halonen, L. M. Taussig,
A. L. Wright, and F. D. Martinez. 1999. Respiratory syncytial virus in early life
and risk of wheeze and allergy by age 13 years. Lancet 354: 541–545.
13. Sigurs, N., P. M. Gustafsson, R. Bjarnason, F. Lundberg, S. Schmidt,
F. Sigurbergsson, and B. Kjellman. 2005. Severe respiratory syncytial virus
bronchiolitis in infancy and asthma and allergy at age 13. Am. J. Respir. Crit.
Care Med. 171: 137–141.
14. Piippo-Savolainen, E., S. Remes, and M. Korppi. 2007. Does blood eosinophilia
in wheezing infants predict later asthma? A prospective 18-20-year follow-up.
Allergy Asthma Proc. 28: 163–169.
15. Openshaw, P. J. M. 2003. RSV bronchiolitis, gammadelta T cells and asthma: are
they linked? Clin. Exp. Immunol. 131: 197–198.
16. Culley, F. J., J. Pollott, and P. J. Openshaw. 2002. Age at first viral infection
determines the pattern of T cell-mediated disease during reinfection in adulthood. J. Exp. Med. 196: 1381–1386.
17. Dakhama, A., J. W. Park, C. Taube, A. Joetham, A. Balhorn, N. Miyahara,
K. Takeda, and E. W. Gelfand. 2005. The enhancement or prevention of airway
hyperresponsiveness during reinfection with respiratory syncytial virus is critically dependent on the age at first infection and IL-13 production. J. Immunol.
175: 1876–1883.
18. Becnel, D., D. You, J. Erskin, D. M. Dimina, and S. A. Cormier. 2005. A role for
airway remodeling during respiratory syncytial virus infection. Respir. Res. 6: 122.
19. You, D., D. Becnel, K. Wang, M. Ripple, M. Daly, and S. A. Cormier. 2006.
Exposure of neonates to respiratory syncytial virus is critical in determining
subsequent airway response in adults. Respir. Res. 7: 107.
20. Lee, H. H., C. M. Hoeman, J. C. Hardaway, F. B. Guloglu, J. S. Ellis, R. Jain,
R. Divekar, D. M. Tartar, C. L. Haymaker, and H. Zaghouani. 2008. Delayed
maturation of an IL-12-producing dendritic cell subset explains the early Th2
bias in neonatal immunity. J. Exp. Med. 205: 2269–2280.
21. Kim, H. W., J. G. Canchola, C. D. Brandt, G. Pyles, R. M. Chanock, K. Jensen,
and R. H. Parrott. 1969. Respiratory syncytial virus disease in infants despite prior
administration of antigenic inactivated vaccine. Am. J. Epidemiol. 89: 422–434.

4811

